A phase III trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] plus rituximab vs CHOP plus iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas.

Trial Profile

A phase III trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] plus rituximab vs CHOP plus iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 01 Jun 2017 Planned End Date changed from 1 Aug 2004 to 1 Jun 2017.
    • 06 Dec 2016 Results (n=531) of long term followup, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top